Dr. Lark Embraces Imagenetix's Celadrin in New Formula for Women's Complete Joint Support.

Business Editors/Health/Medical Writers

SAN DIEGO--(BUSINESS WIRE)--Nov. 24, 2003

Imagenetix, Inc. www.imagenetix.net (OTCBB:IAGX) announces that Dr. Susan Lark, one of the world's leading authorities in the field of clinical nutrition and women's health, is recommending a revolutionary, natural joint health formula for women which includes Imagenetix's scientifically studied proprietary compound called Celadrin(R).

Dr. Lark is the author of The Lark Letter, a monthly newsletter that is distributed to an extensive subscriber list throughout North America www.drlark.com. She has appeared on numerous radio and television shows, and she has been featured in magazines and newspapers including: Reader's Digest, McCall's, Better Homes & Gardens, New Woman, Mademoiselle, Harper's Bazaar, Redbook, Family Circle, Seventeen, Shape, Great Life, Real Simple, The New York Times, The Chicago Tribune, and The San Francisco Chronicle. Dr. Lark has also served as a consultant to major corporations, including the Kellogg Company and was a spokesperson in 2002 for The Gillette Company Women's Cancer Connection.

According to Dr. Lark, natural approaches to joint health that include only, Glucosinine, and Chondroitin do not get to the root cause of joint discomfort for women, they either don't do enough, or they take way too long to give the needed support. Dr. Lark's new natural-health product called Daily Balance Joint Answer for Women, is designed to address the joint health, flexibility and mobility of women, and is comprised of Celadrin, Assalix, fish oils, polygonum cuspidatum extract, and glucosamine sulfate. Dr. Lark's joint-health formula is available exclusively through Doctors' Preferred, Inc., (DPI), a subsidiary of Phillips Health, and one of the largest North American direct-mail supplement distributors.

Strong science led to Dr. Lark's inclusion of Celadrin in her formula. In one double-blind placebo-controlled human trial which was recently published in the Journal of Rheumatology, Celadrin was shown to help increase joint flexibility, improve flat ground walking, as well as traversing up and down stairs. A significant side benefit reported by the study participants who consumed Celadrin was the ability to significantly get a better night's sleep.

About Dr. Susan Lark

Dr. Susan Lark, is one of the foremost authorities in the fields of clinical nutrition and preventive medicine. A graduate of Northwestern University Medical School, she served on the clinical faculty of Stanford University Medical School from 1981-1983, and taught in Stanford's Primary Care Associate Program in the Division of Family and Community Medicine from 1991-2002.

Dr. Lark is a distinguished clinician, author, lecturer and innovative product developer. Through her 28 years of clinical experience, she has pioneered the use of self-care treatments such as diet, nutrition, exercise and stress management techniques in the field of women's health, and has lectured extensively throughout the United States on topics in preventive medicine. She has also published her ground-breaking therapies in a nine-book series that includes the Premenstrual Syndrome Self Help Book, the Menopause Self Help Book and Anxiety and Stress, among others. With her husband, James A. Richards, MBA, she has also co-authored The Chemistry of Success: Six Secrets of Peak Performance.

Dr. Lark's mission is to provide women with unique, safe and effective complementary therapies to greatly enhance their health and well-being.

About Phillips Health

Phillips Health, LLC, a Phillips International, Inc. company, is a recognized leader in providing authoritative health solutions to consumers. In addition to producing online resources and publishing newsletters, Phillips Health includes its subsidiary, Doctor's Preferred, Inc. (DPI), a vitamin and nutritional supplement business that markets primarily through direct mail. Located in the greater Washington, D.C. area, Phillips International (www.phillips.com) is a leading publisher in America. The privately held company provides quality products and services for the health and investment marketplaces.

About Imagenetix

San Diego based Imagenetix, Inc. is an innovator of scientifically tested, natural-based, proprietary bioceutical products developed to enhance human and animal health on a global basis. The Company develops leading edge topical creams, skin care products, and nutritional supplements to be marketed globally through multiple channels of distribution. In addition, Imagenetix develops patentable compounds for the purpose of entering into licensing agreements with pharmaceutical partners.

Rather than market products directly to consumers, Imagenetix markets to business organizations who in turn market the products to consumers through their own private labels. Imagenetix has developed a "turnkey" approach to assist these organizations with product distribution to consumers. Distribution of products by Imagenetix clients is currently underway through direct selling, mass market, medical, health, and nutritional professionals, medical newsletters, direct response radio, and through direct response television, and other channels of distribution.

Safe Harbor Statement

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. These factors and others could cause operating results to vary significantly from those in prior periods and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company expects to file with the Securities Exchange Commission.